首页> 外文OA文献 >Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

【2h】

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

机译：单一试剂对复发和难治外周T细胞淋巴瘤的组合化疗：外周T细胞淋巴瘤治疗（完整）注册表的综合肿瘤措施结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Robert N. Stuver; Niloufer Khan; Marc Schwartz; Mark Acosta; Massimo Federico; Christian Gisselbrecht; Steven M. Horwitz; Frederik Lansigan; Lauren C. Pinter‐Brown; Barbara Pro; Andrei R. Shustov; Francine M. Foss; Salvia Jain;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry [J] . Stuver Robert N., Khan Niloufer, Schwartz Marc, American Journal of Hematology . 2019,第6期

机译：单一剂对复发和难治性外周T细胞淋巴瘤的组合化疗：外周T细胞淋巴瘤治疗（完整）注册表的综合肿瘤学措施
2. Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry [J] . Stuver Robert, Khan Niloufer, Schwartz Marc, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单药剂和组合化疗策略在复发/难治性外周T细胞淋巴瘤中的作用：完整登记处的结果
3. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. [J] . Viviani S, Di Nicola M, Bonfante V, Leukemia and lymphoma . 2010,第7期

机译：大剂量化学疗法加自体骨髓或外周干细胞移植作为复发或难治性霍奇金淋巴瘤的首次抢救治疗的长期结果：单一机构经验。
4. ELEVATION OF MINIMAL RESIDUAL DISEASE (MRD) IN THE PERIPHERAL BLOOD PRIOR TO THE CLINICAL RELAPSE IN DOGS WITH LYMPHOMA THAT ACHIEVED COMPLETE REMISSION AFTER CHEMOTHERAPY [C] . Masahiko Sato, Junpei Yamazaki, Yuko Goto-Koshino, Annual Conference of the Veterinary Cancer Society . 2009

机译：在淋巴瘤患者临床复发之前在外周血中的最小残留疾病（MRD）升高，从而在化疗后取得完全缓解
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma [O] . Owen A. O’Connor, Muhit Özcan, Eric D. Jacobsen, -1

机译：复发或难治性外周T细胞淋巴瘤患者中Alisertib或研究者选择的药物（选定的单药）随机III期研究
7. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma. [O] . Tiffany Tang, Peter Martin, Nagavalli Somasundaram, 2020

机译：I阶段研究Selinexor与地塞米松，Ifosfamide，Carboplatin，复发或难治性外周T细胞或Naturalkiller / T细胞淋巴瘤患者的依托普齐德化疗。

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

著录项

相似文献

相关主题

期刊订阅